Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer, covers the month of July 2020. The report, dated July 22, 2020, consists solely of a press release issued on that date, which is attached as Exhibit 99.1 and incorporated by reference.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a vehicle to distribute a press release and does not contain a financial statement or quantitative performance data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational metrics are included in the cover page or summary text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. While the filing incorporates a press release by reference, the specific content of that release is not detailed in the provided text.
Key Facts for Investor Verification
- The filing is a Form 6-K dated July 22, 2020, signed by CEO Adam Gridley.
- The report contains no standalone financial data; investors must review the attached Exhibit 99.1 (Press Release) for specific corporate updates.
- The company is headquartered in Jerusalem, Israel, and files annual reports on Form 20-F.